NAD⁺ decline in ageing: where peptides fit a small-molecule-dominated field
Nicotinamide adenine dinucleotide (NAD⁺) decline across adulthood is among the most heavily studied metabolic hallmarks of ageing, given the molecule's central role as a cofactor for hundreds of redox reactions and as substrate for sirtuin deacetylases and PARP DNA-repair enzymes. Massudi et al. (2012, PLOS ONE) and subsequent work confirmed a substantial age-related decline in tissue NAD⁺ levels across multiple human and animal tissue types, and this decline is now a standard reference point in ageing-biology funding and trial design.
The dominant intervention strategy is small-molecule NAD⁺ precursor supplementation, principally nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). Both are converted through the salvage pathway to raise cellular NAD⁺ levels, and both have progressed to human trials, including Irie et al. (2020, Endocr J) for NMN and Martens et al. (2018, Nat Commun) for NR, with generally favourable safety profiles and modest biomarker improvements. It is worth being direct about this: no peptide in the current research catalogue raises NAD⁺ levels through this precursor route, and framing peptides as NAD-boosting agents would misrepresent the mechanism.
Where peptides intersect this field is adjacent to, rather than through, the NAD⁺ salvage pathway. MOTS-c is the clearest example: as a mitochondrially-encoded peptide that activates AMPK under metabolic stress, its downstream signalling overlaps with sirtuin biology, since AMPK activation and NAD⁺-dependent SIRT1 activity are mutually reinforcing in the cellular energy-sensing network described by Cantó et al. (2009, Cell Metab). MOTS-c does not raise NAD⁺ directly, but its activation of the same energy-sensing axis that NAD⁺ precursors are intended to support gives it a mechanistically coherent, if indirect, place in this research area.
SS-31 offers a second, distinct point of intersection. Its mechanism — stabilising cardiolipin in the inner mitochondrial membrane to preserve electron-transport-chain efficiency — addresses a downstream consequence of the same mitochondrial dysfunction that NAD⁺ decline is thought to contribute to, namely impaired oxidative phosphorylation and increased reactive-oxygen-species leakage. Siegel et al. (2013, Aging Cell) and subsequent work describe SS-31's effect on aged-muscle mitochondrial function in terms that are complementary to, rather than overlapping with, the NAD⁺-precursor mechanism.
Sirtuin biology itself deserves a note of caution independent of any specific peptide. The original Guarente-lab yeast Sir2 lifespan-extension findings that popularised sirtuins as a longevity target were substantially more complicated to replicate cleanly across species than early coverage suggested, and the field has since moved toward a more measured view in which sirtuins are one node within a broader NAD⁺-dependent regulatory network rather than a standalone master switch. Any peptide research programme referencing sirtuin biology should carry this same caution rather than overstating a direct causal chain.
Hyperbaric oxygen therapy (HBOT) is sometimes discussed alongside NAD⁺ and mitochondrial biology in the broader longevity literature, including Hachmo et al. (2020, Aging) reporting increased telomere length and reduced senescent T-cell fraction in older adults following a HBOT protocol. This sits outside the peptide-research scope of this catalogue and is noted here only to mark the boundary: HBOT is a physical intervention, not a peptide or small-molecule pharmacological one, and is not further addressed on this site.
The practical research question for this catalogue is not whether a peptide can replace NAD⁺ precursor supplementation, since none is designed to, but whether MOTS-c or SS-31 produce additive benefit when studied alongside NMN or NR in a combined protocol. The mechanistic rationale — one axis raising substrate availability, the other supporting the energy-sensing and membrane-integrity systems that use that substrate — is plausible but has not been directly tested in a controlled comparison.
A further open question concerns tissue specificity. NAD⁺ decline is not uniform across organs, and skeletal muscle, liver and brain show different rates and consequences of decline in the existing literature. MOTS-c's exercise-mimetic activity is best characterised in skeletal muscle specifically, which raises the question of whether its NAD-adjacent benefit is similarly tissue-restricted rather than systemic.
The research opportunity in 2026 is a structured comparison: NAD⁺ precursor alone, MOTS-c or SS-31 alone, and combined protocols, using consistent tissue-specific NAD⁺ and mitochondrial-function biomarkers rather than the mixed endpoint panels currently scattered across separate small trials. Until that comparison exists, the honest position is that peptides play a supporting, mechanistically distinct role in NAD⁺-related ageing research rather than a central one.